MEDICAL

Ochre Bio Launches ‘Liver ICU’ in the United States to Evaluate Effects of RNA Therapies on Human Liver Performance

Ochre Bio | May 12, 2022

Ochre_Bio_Launches
Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced today the launch of their ‘Liver ICU’. Housed in BioLabs@NYULangone, a biopharma incubator in New York City, this research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines. The use of discarded donor livers for research is expected to enhance timelines and accuracy of liver medicine research by testing interventions directly in human livers maintained under conditions mimicking human physiology.

This site is a part of a network of three leading liver perfusion research sites across the US. The other two US research sites are the laboratory of Greg Tietjen, Ph.D at Yale University, a pioneer in the field of ex vivo organ research, and LifeShare of Oklahoma, a leading US organ procurement organization. In addition, Ochre Bio is also announcing a partnership with OrganOx, a company at the forefront of changing the way donor livers are preserved in the critical time between donation and transplantation, and one of the first companies to have a liver perfusion device approved by the FDA.

This research will involve hundreds of donor livers being kept alive outside the body for multiple days each. These are donor livers that cannot be used for transplant patients for various reasons, and so would be otherwise discarded. The livers will be maintained in human physiological conditions and used to test therapeutic interventions, with the goal of finding new therapies to improve liver transplant outcomes, in the hopes of thereby increasing the supply of transplantable livers, as well as uncovering insights relevant to a wider set of liver diseases. Greg Tietjen’s research group at Yale and LifeShare of Oklahoma will work with the Ochre research team towards being able to consistently perfuse organs for several days to study the effects of RNA therapy on liver performance.

We’re excited to announce this new research site in the US, as well as these partnerships with world leaders in liver perfusion research and transplant medicine, This collaboration to evaluate the effects of RNA therapy directly in human livers preclinically is a step change for liver research, that we hope will lead to treatments for a number of liver diseases, and one day reduce the burden of liver transplantation for patients.”

Jack O’Meara, CEO & Co-Founder at Ochre Bio.

Thanks to the collaborative efforts of Ochre Bio, OrganOx, Yale University and, LifeShare of Oklahoma, the unique capabilities of the OrganOx metra are enabling multi-day isolated organ perfusion research and facilitating a new and exciting approach to developing novel therapeutics for liver diseases. We look forward to seeing the results of this approach leave research and enter the clinic in the future.” 

Craig Marshall, CEO, OrganOx.

We view this work as an opportunity to honor the profound gift that every donor organ represents. While the organs enrolled in this study may not save the life of one transplant recipient, they have the potential to save hundreds of thousands of lives in the future by enabling breakthrough new therapies from Ochre Bio to treat end stage liver disease.” 

Gregory Tietjen, Ph.D., Assistant Professor of Transplant Surgery, Yale School of Medicine

About Ochre Bio
Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. With laboratories across the UK, Asia and North America, the team has decades of experience leading liver genomics research and bringing advanced therapies to market.

Spotlight

As you head off to the beach this summer with your family and friends, biotechnology is probably the last thing on your mind. What you might not realize is the vast amount of potential that the world's oceans hold for curing disease.


Other News
MEDICAL

Slingshot Biosciences, Inc. Partners With Cambridge Bioscience to Distribute Synthetic Cells Throughout United Kingdom and Ireland

Slingshot | June 16, 2022

SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Cambridge Bioscience, a UK-based specialist distributor of life science research tools. The agreement entitles Cambridge Bioscience to the right to distribute and resell Slingshot Bio’s products in the United Kingdom and Ireland. Through Cambridge Bioscience’s network of customers, Slingshot Bio will be able to establish its presence in the United Kingdom and Ireland market with the well-established presence and expertise of Cambridge Bioscience which has been selling into flow cytometry for many years. Cambridge Bioscience’s network will provide us with the market penetration needed to reach our full sales potential. Slingshot Biosciences has considered many distribution partners and we are confident that Cambridge Bioscience’s extensive knowledge in the field, prominent presence, and large customer base will help us leverage our position in the flow cytometry market.” Jeffrey Kim, CEO & Founder. About Slingshot Biosciences, Inc. Founded in 2012, Slingshot Biosciences is a fast-growing life sciences company with a platform technology and paradigm-shifting mission to make synthetic cells the gold standard for all cell-based applications—including diagnostics, and adoptive cell therapy development and instrument calibration.

Read More

MEDICAL

Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers

Ratio Therapeutics | June 13, 2022

Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial scientists Jack Hoppin, Ph.D., and John Babich, Ph.D., Ratio emerges from stealth mode with more than $20 million in seed funding, fully funded development alliances with Bayer AG and Lantheus Holdings Inc., a robust portfolio of assets developed with two proprietary technologies, and a growing team of world-class experts in radiopharmaceuticals discovery and development. The company's near-term plans call for the submission of its first investigational new drug (IND) applications, which are expected this quarter, and the initiation of clinical trials later this year. Based in Boston, Ratio is set to move to a new 19,000-square-foot headquarters and research facility in the Seaport District in January. Ratio's radiopharmaceuticals strategy is focused on optimizing tumor localization while minimizing uptake by normal tissues. To achieve this, the company uses its proprietary technology platform called Trillium™ that is based on Dr. Babich's prior research at Weill-Cornell Medical College and first developed and validated by the founders in a previous venture. Trillium is a trifunctional small molecule scaffold that can be fine-tuned to alter its plasma clearance, target affinity and therapeutic payload. Each component of the scaffolding can be independently optimized to boost tumor uptake over normal tissue uptake, thereby maximizing therapeutic index. Ratio has successfully applied this framework to several tumor targets and multiple therapeutic payloads. In addition, Ratio is developing a technology platform to take advantage of the tumor killing power of the alpha emitter, Actinium-225. This proprietary technology is called the Macropa™ chelate platform. Ratio's scientists have already successfully incorporated Macropa into the Trillium platform as well as several peptides and antibodies. Macropa's unique chemistry enables ease of manufacture and robust in vitro and in vivo stability of the resulting radiotherapeutic compound. The ability to fine-tune our targeted radiotherapeutics using Trillium and Macropa enables us to address head-on the trifecta of typical challenges we see with most radiopharmaceuticals: delivery, safety and efficacy, Over the past year, we have generated significant preclinical data that demonstrate our ability to create excellent performing drug candidates that now are advancing into the clinic. Our goal is to become the partner of choice for pharmaceutical companies committed to this area of cancer therapy by enabling the optimization of a broad array of targeting compounds. We will shepherd these therapies through early clinical studies on our own or in collaboration." Dr. Babich, Ratio's President and Chief Scientific Officer. Targeted radiotherapy is an exciting and emerging field where chemistry meets physics meets medicine. We have assembled and will continue to build a world-class interdisciplinary team of researchers and developers with a singular focus on delivering these treatments to cancer patients. It isn't often that a start-up company has in place the early financial backing and industry support to advance entirely new drug discoveries to clinical development at this pace. It is with great pride that we announce our formal launch and exit from stealth mode." Dr. Hoppin, Ratio's Chairman and Chief Executive Officer. In collaboration with Bayer, Ratio has leveraged its Trillium platform for the identification of lead prostate-specific membrane antigen (PSMA)-targeted therapeutic compounds for prostate cancer. At the same time, Ratio is working with Lantheus to develop a lead fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers, such as breast, pancreatic, lung and stomach cancer. Both collaborations are fully funded and reflect the types of partnerships that Ratio is currently pursuing with other companies. About Ratio Therapeutics Ratio Therapeutics Inc. is a Boston-based pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. Founded by John Babich, Ph.D., and Jack Hoppin, Ph.D., the company currently employs a growing team of radiopharmaceuticals discovery and development experts with backgrounds in the life science industry. Ratio's fully integrated proprietary R&D platforms, Trillium™ and Macropa™, enable the imaging, discovery and advancement of novel radiopharmaceuticals that have first/best-in-class delivery, safety and efficacy properties. The tunable nature of the company's platforms enables the efficient and timely generation of numerous novel radiopharmaceuticals for a broad range of high unmet need in solid tumors. Built to be the radiopharmaceuticals discovery and development partner of choice, Ratio currently collaborates with Bayer and Lantheus.

Read More

RESEARCH

Lunaphore and Indica Labs announce partnership to provide complete technology solution for spatial biology and image analysis

Indica Labs | May 13, 2022

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Indica Labs, a leading provider of computational pathology software and services, today announced a partnership to co-market an end-to-end solution that combines Lunaphore's flagship COMET™ spatial biology platform and Indica's HALO® and HALO AI™ digital pathology image analysis software. Lunaphore's COMET™ platform provides superior multiplex staining and image acquisition capabilities facilitating the automated detection of up to 40 separate spatial markers per tissue slide without human intervention. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free antibodies and is designed to provide researchers with flexibility for their workflow. COMET™ has a wide range of research applications across immuno-oncology, neuroscience, and infectious diseases. Indica Labs' industry-leading HALO® and HALO AITM software enable fast, AI-based quantitative analysis of whole slide images. In combination with the COMET™ platform, the HALO Highplex FL module allows researchers to quantify an unlimited number of fluorescent markers and cell phenotypes defined by their biomarker expression. HALO Spatial Analysis and HALO AI deep learning classifiers are used in combination with Highplex FL to explore the distribution and spatial relationships between different cell phenotypes in the context of the tissue, such as tumor and immune cells. This additional spatial data is particularly important in immuno-oncology and neuroscience disease research. We are excited to partner with Lunaphore to address the growing needs of our research customers for highly multiplexed assays, Combining Lunaphore's superior multiplexing technologies upstream with our powerful AI-based analysis downstream, together we provide a streamlined workflow for high dimensional imaging and image analysis." Steven Hashagen, CEO of Indica Labs. Our partnership with Indica Labs is another key aspect of our strategy to combine our COMET™ technology with industry-leading image analysis technologies, Indica Labs' solutions are used by a large set of researchers in the field, thanks to their ease of use and analysis capabilities. Combining Indica's solutions with the class-leading capabilities of COMET™ will help us pursue our shared goal of making tissue image analysis easier and more accessible to labs around the world." Deborah Heintze, Chief Marketing Officer of Lunaphore. About Lunaphore Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. About Indica Labs Indica Labs is the world's leading provider of computational pathology software and image analysis services. Our flagship HALO® and HALO AI™ platform facilitates quantitative evaluation of digital pathology images. HALO Link™ facilitates research-focused image management and collaboration while HALO AP® enables collaborative clinical case review. Our Pharma Services team leverages all our image analysis platforms to partner with you to advance tissue-based research, clinical trials, and diagnostics.

Read More

MEDICAL

Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study

BioVaxys | June 09, 2022

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its Lyon, France-based bioproduction partner, BioElpida ("BioElpida"), has completed the creation of multiple OVCAR-3 cell banks as the next step in the GMP manufacturing process development for BVX-0918, BioVaxys' vaccine for treatment of platinum-resistant ovarian cancer. The OVCAR-3 cell line is mandatory for creating the identity assays that will have to be performed on every batch of ovarian cancer vaccine. This assay is required by regulatory bodies in the EU and United States. The cell line is derived from a human ovarian adenocarcinoma, established from a patient refractory to cisplatin, a chemotherapeutic agent used in late-stage ovarian cancer. Patients whose tumors are innately cisplatin-resistant at the time of initial treatment generally have poor prognosis, which is the patient population target for BVX-0918. Completion of OVCAR-3 cell banks is another step towards our ability to produce GMP yields of BVX-0918, and brings us closer to our Phase I study in the EU planned for later this year." BioVaxys President and Chief Operating Officer Kenneth Kovan. BioVaxys recently entered collaborations with Hospices Civils de Lyon in France and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients. Tumor samples from both hospitals are being used to validate the tumor collection protocol, cryopackaging, cryopreservation, and supply chain logistics for BVX-0918 bioproduction for prospective patients in the US and EU. Tumor samples from HCL will also be used for process testing and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process ("GMP") production. BioVaxys' vaccine platform is based on the established immunological concept that modifying surface proteins---whether they are viral or tumor---with haptens makes them more visible to the immune system. This process of haptenization "teaches" a patient's immune system to recognize and make target proteins more "visible" as foreign, thereby stimulating a T-cell mediated immune response. BioVaxys' cancer vaccines are created by extracting a patient's own (autologous) cancer cells, chemically linking with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic. Haptenization is a well-known and well-studied immunotherapeutic approach to cancer immunotherapy and has been clinically evaluated in both regional and disseminated metastatic tumors. A first generation single-hapten vaccine invented by BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, achieved positive immunological and clinical results in Phase I and Phase II human trials in over 600 patients with different tumor types, as well as having no observed toxicity in years of clinical study. These studies were conducted under an FDA-reviewed IND. A first generation autologous, haptenized vaccine was also tested by Dr. Berd in women with advanced ovarian cancer who had ceased to respond to conventional chemotherapy. The results were encouraging: In 24 patients, the median overall survival was 25.4 months with a range of 4.5-57.4 months; 8 patients survived for more than 2 years. BioVaxys has enhanced the first-generation approach by utilizing two haptens ("bi-haptenization"), which the Company believes will yield superior results. About BioVaxys Technology Corp. Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).

Read More

Spotlight

As you head off to the beach this summer with your family and friends, biotechnology is probably the last thing on your mind. What you might not realize is the vast amount of potential that the world's oceans hold for curing disease.

Resources